Improved, personalized treatment of glioma necessitates long-term follow-up of cognitive functioning

Pharmacogenomics

Volumn 13, Issue 15, 2012, Pages 1667-1669

  Reijneveld, Jaap C ^a   Klein, Martin ^a   Taphoorn, Martin Jb ^a,b   Postma, Tjeerd J ^a   Heimans, Jan J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

cognitive functioning; follow up; glioma; quality of life; treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LOMUSTINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCARBAZINE; RINDOPEPIMUT; TEMOZOLOMIDE; VINCRISTINE;

ATTENTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COGNITION; COGNITIVE DEFECT; DETERIORATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; EXECUTIVE FUNCTION; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; MINI MENTAL STATE EXAMINATION; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; PSYCHOLOGIC TEST; QUALITY OF LIFE; WORKING MEMORY;

BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COGNITION; GLIOMA; HUMANS; INDIVIDUALIZED MEDICINE; LONG-TERM CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84870021492     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.172     Document Type: Editorial

References (17)

1. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
2. Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, Phase 3 trial. Lancet Oncol. 13(7), 707-715 (2012).
3. Van Den Bent, MJ, Brandes AA, Taphoorn MJB et al. Long term follow-up results of EORTC 26951: a randomized Phase II study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors - a report of the EORTC brain tumor group. Neuro Oncol. 14(Suppl. 3) iii12 (2012).
4. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353(19), 2012-2024 (2005). (Pubitemid 41609094)
5. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010).
6. Froklage FE, Reijneveld JC, Heimans JJ. Central neurotoxicity in cancer chemotherapy: pharmacogenetic insights. Pharmacogenomics 12(3), 379-395 (2011).
7. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 3(3), 159-168 (2004). (Pubitemid 38229950)
8. Taphoorn MJ, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 6(12), 937-944 (2005). (Pubitemid 41685226)
9. Taphoorn MJ, van den Bent MJ, Mauer ME et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J. Clin. Oncol. 25(36), 5723-5730 (2007).
10. Wang M, Cairncross G, Shaw E et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int. J. Radiat. Oncol. Biol. Phys. 77(3), 662-669 (2010).
11. Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. J. Clin. Oncol. 22(5), 966-967 (2004).
12. Archibald YM, Lunn D, Ruttan LA et al. Cognitive functioning in long-term survivors of high-grade glioma. J. Neurosurg. 80(2), 247-253 (1994). (Pubitemid 24036495)
13. Douw L, Klein M, Fagel SS et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 8(9), 810-818 (2009).
14. Klein M, Heimans JJ, Aaronson NK et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360(9343), 1361-1368 (2002). (Pubitemid 35341299)
15. Steinbach JP, Blaicher HP, Herrlinger U et al. Surviving glioblastoma for more than 5 years: the patient's perspective. Neurology 66(2), 239-242 (2006). (Pubitemid 43970162)
16. Flechl B, Ackerl M, Sax C et al. Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. J. Neurooncol. 109(2), 331-339 (2012).
17. Habets EJJ, Taphoorn MJB, Nederend S et al. Cognitive functioning and health related quality of life in long term anaplastic glioma survivors from EORTC study 26951. Neuro Oncol. 14(Suppl. 3), iii4-iii5 (2012).